RepliCel Life Sciences Balance Sheet Health
Financial Health criteria checks 0/6
RepliCel Life Sciences has a total shareholder equity of CA$-5.2M and total debt of CA$1.3M, which brings its debt-to-equity ratio to -25.2%. Its total assets and total liabilities are CA$151.0K and CA$5.3M respectively.
Key information
-25.2%
Debt to equity ratio
CA$1.31m
Debt
| Interest coverage ratio | n/a |
| Cash | CA$10.47k |
| Equity | -CA$5.19m |
| Total liabilities | CA$5.34m |
| Total assets | CA$150.97k |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: P6P2 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: P6P2 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: P6P2 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: P6P2's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: P6P2's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if P6P2's interest payments on its debt are well covered by EBIT.